综合性胰腺癌分析显示,LPCAT1是一种用于预后和免疫治疗反应的新型预测生物标志物
Hongyu Gao1,2, Jinfeng Zhu1,2, Tong Wu1,2
1Department of General Surgery, The Second Xiangya Hospital of Central South University, Changsha, Hunan, China.
概括
Lysophosphatidylcholine acyltransferase 1 (LPCAT1) 在许多癌症中被上调,与预后不佳相关,并影响瘤进展和免疫反应. 向LPCAT1可能会改善癌症治疗结果和免疫疗法的疗效.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
背景情况:
- Lysophosphatidylcholine酸转移酶1 (LPCAT1) 对脂代谢和生物膜完整性至关重要.
- 它在不同类型的癌症中的作用及其对抗瘤免疫力的影响在很大程度上仍未被描述.
研究的目的:
- 为了全面调查LPCAT1在各种癌症中的作用.
- 探索其与预后,生物功能和抗瘤免疫的关联.
主要方法:
- 对LPCAT1表达,遗传变异,甲基化和预后价值的公共数据库的分析.
- 在瘤,乳腺和肝癌细胞中的体外实验验以验证LPCAT1的功能.
- 功能性丰富分析和免疫细胞透和免疫检查点基因表达的评估.
主要成果:
- 在多种癌症中,LPCAT1的升级调节,通常具有放大突变,并且与较差的患者预后有关.
- 实验室研究表明,抑制LPCAT1会增加细胞亡,抑制癌细胞的增殖和迁移.
- LPCAT1的表达与免疫细胞透,免疫检查点基因相关,在免疫疗法响应者中更高.
结论:
- LPCAT1在瘤进展和免疫调节中起着重要作用.
- LPCAT1是一种有前途的生物标志物,可以预测癌症患者的治疗结果和免疫治疗的反应,特别是与PDL1结合使用.
相关概念视频
02:39lncRNA - Long Non-coding RNAs
8.5K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.5K
01:21Cancer Survival Analysis
334
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
334